

## Supporting Published Statements

1. American Diabetes Association, Position Statement: Aspirin Therapy in Diabetes. *Diabetes Care*. 2003, January 26; (Supplement 1):S87-S88.
2. American Diabetes Association, Position Statement: Aspirin Therapy in Diabetes. *Diabetes Care*. 1998, January 21; (Supplement 1): 057-058
3. U.S. Prevention Services Task Force. Aspirin for the Primary Prevention of Cardiovascular Events: Recommendation and Rationale. *Ann Intern Med* 2002 January 15; 136(2):157-160.
4. Hayden M, Pignone M, Phillips C and Mulrow C., Aspirin for the primary prevention of cardiovascular Events: A summary of the evidence for the US Preventive Services Task Force. *Ann Intern Med* 2002; 136:161-172.
5. Pearson TA, Blair SN, Daniels SR, et al. AHA Guidelines for primary prevention of cardiovascular disease and stroke: 2002 Update; Consensus Panel Guide to comprehensive disease and stroke: 2002 Update; Consensus Panel Guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. *Cir* 2002;106:388-391
6. Hennekens, C.H.; Dyken, M.L., and Fuster, V. Aspirin as a therapeutic agent in cardiovascular disease: A statement for healthcare professionals from the American Heart Association. *Circulation: American Heart Association*. 1997 Oct 21; 96(8):2751-3.
7. Augustovski F., Aspirin for primary prevention of cardiovascular events. *Journal of General Internal Medicine* 1998;13:824-835.
8. Assman G, Rafael, C. Cullen, P, et al. Coronary heart disease: Reducing the risk, A worldwide view. *Cir: American Heart association*. 1999; 100:1930-1938.
9. Cairns, J., Thérroux, P. et al., Antithrobotic agents in coronary artery disease. *CHEST* 1998 November 5; 114:611S-633S.
10. Colwell, J. Aspirin therapy in diabetes. *Diabetes Care*, 1997 November 11; (20):1767-1771.
11. Eidelman RS, Herbert, P, Weisman S, Hennekens, CH. An update on aspirin in the primary prevention of cardiovascular disease. 2003 *Archives of internal medicine* IN PRESS.

12. Herbert PR, Hennekens CH. An overview of the 4 randomized trials of aspirin therapy in the primary prevention of vascular disease. *Arch Intern Med* 2000;160:3123-3127.
13. Lauer MS., Clinical Practice. Aspirin for primary prevention of coronary events. *N Engl J Med.* 2002;346:1468-74.
14. Mehta, P. Aspirin in the prophylaxis of coronary artery disease. *Curr Opin Cardiol* 2002; 17:552-558, Lippincott Williams & Wilkins, Inc., 2002.
15. Passa, P., Reducing the cardiovascular consequences of diabetes mellitus. *Diabetic Medicine* 1998; (15) ;(Supplement 4):S69-S72.
16. Patrono, C., Platelet active drugs the relationship among dose, effectiveness and side effects. *Chest* 1998; 114:470S-488S.
17. Sanmuganathan P.S., Aspirin for primary prevention of coronary heart disease, safety and absolute benefit related coronary risk derived from meta-analysis of randomized trials. *Heart* 2001;85:265-271.